Adapt Pharma® Launches Roll Call Training Video to Educate Law Enforcement on NARCAN® (naloxone HCI) Nasal Spray 4mg
October 17, 2017
ADAPT PHARMA® LAUNCHES ROLL CALL TRAINING VIDEO
TO EDUCATE LAW ENFORCEMENT ON NARCAN® (naloxone HCI) NASAL SPRAY 4MG
Customizable On-Shift Training Designed with Law Enforcement Needs at the Forefront
Dublin, Ireland – October 17, 2017 – Adapt Pharma, Inc. (www.adaptpharma.com) today launched a new roll call training video to educate law enforcement on proper administration of NARCAN® (naloxone HCI) Nasal Spray 4mg to help reverse the effects of an opioid overdose. This roll call instructional video can be downloaded from Narcan.com/LawEnforcementTrainingVideo and customized to include a personalized introduction from law enforcement leadership.
“The opioid overdose crisis has stretched every local community,” said Karen Tandy, Administrator, U.S. Drug Enforcement Administration (ret.). “We commend Adapt Pharma for providing this educational tool to help law enforcement and first responders prepare and quickly respond during an emergency situation.”
Naloxone helps reverse the effect of a potentially fatal opioid overdose and is increasingly being used by first responders to fight the nationwide epidemic. NARCAN® Nasal Spray 4mg is the only FDA-approved, needle-free formulation of naloxone that does not require assembly or any specialized medical training. It is also the highest concentrated dose of intranasal naloxone currently available. Additional doses of NARCAN® Nasal Spray may be required until emergency medical assistance arrives.
“When responding to an opioid emergency, response time, naloxone dose strength and rapid administration are three essential elements,” said Mike Kelly, President, U.S. Operations, Adapt Pharma. “This training video reinforces the intuitive process of delivering NARCAN® Nasal Spray, enabling our law enforcement to act fast and focus on helping those at risk when every second counts.”
“Law enforcement agencies are often first on the scene of an opioid overdose,” said 2nd Vice President of the National Sheriff’s Association and Sheriff of Hennepin County, Minnesota, Rich Stanek. “This video gives us the ability to do necessary on-shift training, allowing us to arm our patrol, emergency services, and jail deputies with NARCAN® Nasal Spray, and train them to manage an overdose situation until emergency care arrives.”
NARCAN® Nasal Spray is not a substitute for emergency medical care, and when used, law enforcement should seek additional medical care. Adapt Pharma® always recommends that individuals review and have a complete understanding of the Patient Information and the Instructions for Use for NARCAN® Nasal Spray.
NARCAN® NASAL SPRAY
NARCAN® Nasal Spray is the first and only FDA-approved naloxone in a nasal spray for the emergency treatment of a known or suspect opioid overdose. It is available as a ready-to-use, needle-free, 4 mg dose of naloxone in a single spray. NARCAN® Nasal Spray is not a substitute for emergency medical care, and repeat applications may be necessary. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.
NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.
Important Safety Information
NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.
Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.
Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, goose bumps (piloerection), yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure and increased heart rate (tachycardia). In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.
Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.
To report SUSPECTED ADVERSE REACTIONS, contact ADAPT Pharma, Inc. at 1-844-4NARCAN (1-844-462-
7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For additional information on NARCAN® Nasal Spray, please visit www.NARCAN.com.
ABOUT ADAPT PHARMA®
Adapt Pharma is a privately-held pharmaceutical company committed to positively impacting the lives of patients. Adapt Pharma’s strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development, and FDA approved, pharmaceutical products. Adapt Pharma’s company headquarters is in Dublin, Ireland and its U.S. headquarters is in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.
ADAPT PHARMA MEDIA CONTACT INFORMATION
Executive Director – Communications